M. Kempf and J. M. Rolain, Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options, Int. J. Antimicrob. Agents, vol.39, issue.2, pp.105-114, 2012.

J. Li, C. R. Rayner, and R. L. Nation, Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii, Antimicrob. Agents Chemother, vol.50, issue.9, pp.2946-2950, 2006.

N. C. Gordon, K. Png, and D. W. Wareham, Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii, Antimicrob. Agents Chemother, vol.54, issue.12, pp.5316-5322, 2010.

, ?? First study showing in vitro synergistic activity of vancomycin-colistin combination on Acinetobacter baumannii

D. W. Wareham, N. C. Gordon, and M. Hornsey, In vitro activity of teicoplanin combined with colistin versus multidrug-resistant strains of Acinetobacter baumannii, J. Antimicrob. Chemother, vol.66, issue.5, pp.1047-1051, 2011.

M. Hornsey and D. W. Wareham, In vivo efficacy of glycopeptide-colistin combination therapies in a Galleria mellonella model of Acinetobacter baumannii infection, Antimicrob. Agents Chemother, vol.55, issue.7, pp.3534-3537, 2011.

, ? Interesting results of colistin-glycopeptide combinations in a Galleria mellonella model of infection

O. Cirioni, O. Simonetti, and E. Pierpaoli, Colistin enhances therapeutic efficacy of daptomycin or teicoplanin in a murine model of multiresistant Acinetobacter baumannii sepsis, Diagn. Microbiol. Infect. Dis, vol.86, issue.4, pp.392-398, 2016.

, Increased survival with colistin-teicoplanin in an A. baumannii murine model of sepsis

J. Garnacho-montero, R. Amaya-villar, and A. Gutiérrez-pizarraya, Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii, Chemotherapy, vol.59, issue.3, pp.225-231, 2013.

G. Ceccarelli, A. Oliva, and G. Ettorre, The role of vancomycin in addition with colistin and meropenem against colistin-sensitive multidrug resistant Acinetobacter baumannii causing severe infections in a paediatric intensive care unit, BMC Infect. Dis, vol.15, issue.1, p.393, 2015.

K. C. Claeys, A. D. Fiorvento, and M. J. Rybak, A review of novel combinations of colistin and lipopeptide or glycopeptide antibiotics for the treatment of multidrug-resistant Acinetobacter baumannii, Infect. Dis. Ther, vol.3, issue.2, pp.69-81, 2014.

M. Wolff, M. L. Joly-guillou, R. Farinotti, and C. Carbon, In vivo efficacies of combinations of beta-lactams, beta-lactamase inhibitors, and rifampin against Acinetobacter baumannii in a mouse pneumonia model, Antimicrob. Agents Chemother, vol.43, issue.6, pp.1406-1411, 1999.

V. Cassisa, J. Pailhoriès, H. Coron, N. Eveillard, and M. , Colistin, rifampicin, and meropenem administered as single agents in a model of pneumonia caused by a carbapenem-resistant Acinetobacter baumannii, J. Infect, vol.69, issue.5, pp.516-517, 2014.

M. Eveillard, C. Soltner, and M. Kempf, The virulence variability of different Acinetobacter baumannii strains in experimental pneumonia, J. Infect, vol.60, issue.2, pp.154-161, 2010.

O. Mimoz, D. Rolland, and M. Adoun, Steady-state trough serum and epithelial liningconcentrations of teicoplanin 12 mg/kg per day in patients withventilator-associated pneumonia, Intensive Care Med, vol.32, pp.775-779, 2006.

Y. Cai, D. Chai, R. Wang, B. Liang, and N. Bai, Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms andantimicrobial strategies, J. Antimicrob. Chemother, vol.67, issue.7, pp.1607-1615, 2012.

K. A. Rodvold, J. M. George, and L. Yoo, Penetration of anti-infective agents intopulmonary epithelial lining fluid: focus on antimicrobial agents, Clin. Pharmacokinet, vol.50, issue.10, pp.637-664, 2011.

C. B. Landersdorfer and R. L. Nation, Colistin: how should it be dosed for thecritically ill?, Semin. Respir. Crit. Care Med, vol.36, issue.1, pp.126-135, 2015.

L. Sorli, S. Luque, and S. Grau, Trough colistin plasma level is an independentrisk factor for nephrotoxicity: a prospective observational cohort study, BMC Infect. Dis, vol.13, p.380, 2013.